Original language | English (US) |
---|---|
Pages (from-to) | 1063-1093 |
Number of pages | 31 |
Journal | European heart journal cardiovascular Imaging |
Volume | 15 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2014 |
Keywords
- Biomarkers
- Chemotherapy
- Doxorubicin
- Early detection
- Left ventricular dysfunction
- Strain
- Three-dimensional echocardiography
- Trastuzumab
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. / Plana, Juan Carlos; Galderisi, Maurizio; Barac, Ana; Ewer, Michael S.; Ky, Bonnie; Scherrer-Crosbie, Marielle; Ganame, Javier; Sebag, Igal A.; Agler, Deborah A.; Badano, Luigi P.; Banchs, Jose; Cardinale, Daniela; Carver, Joseph; Cerqueira, Manuel; DeCara, Jeanne M.; Edvardsen, Thor; Flamm, Scott D.; Force, Thomas; Griffin, Brian P.; Jerusalem, Guy; Liu, Jennifer E.; Magalhães, Andreia; Marwick, Thomas; Sanchez, Liza Y.; Sicari, Rosa; Villarraga, Hector R.; Lancellotti, Patrizio.
In: European heart journal cardiovascular Imaging, Vol. 15, No. 10, 01.10.2014, p. 1063-1093.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy
T2 - A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
AU - Plana, Juan Carlos
AU - Galderisi, Maurizio
AU - Barac, Ana
AU - Ewer, Michael S.
AU - Ky, Bonnie
AU - Scherrer-Crosbie, Marielle
AU - Ganame, Javier
AU - Sebag, Igal A.
AU - Agler, Deborah A.
AU - Badano, Luigi P.
AU - Banchs, Jose
AU - Cardinale, Daniela
AU - Carver, Joseph
AU - Cerqueira, Manuel
AU - DeCara, Jeanne M.
AU - Edvardsen, Thor
AU - Flamm, Scott D.
AU - Force, Thomas
AU - Griffin, Brian P.
AU - Jerusalem, Guy
AU - Liu, Jennifer E.
AU - Magalhães, Andreia
AU - Marwick, Thomas
AU - Sanchez, Liza Y.
AU - Sicari, Rosa
AU - Villarraga, Hector R.
AU - Lancellotti, Patrizio
N1 - Funding Information: The following authors reported no actual or potential conflicts of interest in relation to this document: Juan Carlos Plana, MD, FASE, Maurizio Galderisi, MD, FESC, Marielle Scherrer-Crosbie, MD, PhD, FASE, Javier Ganame, MD, PhD, FASE, Deborah A. Agler, RCT, RDCS, FASE, Luigi P. Badano, MD, PhD, FESC, Jose Banchs, MD, FASE, Daniela Cardinale, MD, Joseph Carver, MD, Thor Edvardsen, MD, PhD, FESC, Brian Griffin, MD, Guy Jerusalem, MD, PhD, Jennifer E. Liu, MD, FASE, Andreia Magalhães, MD, Liza Y. Sanchez, RCS, FASE, Rosa Sicari, MD, PhD, FESC, Hector R. Villarraga, MD, FASE, and Patrizio Lancellotti, MD, PhD, FESC. The following authors reported relationships with one or more commercial interests: Ana Barac, MD, received research funding and lectures honoraria from Genentech and consultancy fees from Cell Therapeutics . Manuel Cerqueira, MD, received a grant from Perceptive Informatics, Inc ; consults for GE Healthcare, FluoroPharma and Astellas; and serves on the speakers bureau for Astellas. Jeanne M. DeCara, MD, served as a consultant for Epsilon Imaging and Methylgene. Michael S. Ewer, MD, JD, consults or serves as advisory board member for Roche Laboratories, Cell Therapeutics, GlaxoSmithKline, and Boehringer Ingelheim. Scott D. Flamm, MD, MBA, serves on advisory boards for Philips Healthcare, Bayer Healthcare, and TeraRecon and received institutional research support from Siemens Healthcare . Thomas Force, MD consults for GlaxoSmithKline. Bonnie Ky, MD, FASE, received an investigator-initiated award from Pfizer, Inc . Thomas Marwick, MBBS, PhD, MPH, received research funding from the National Health and Medical Research Council in Australia and the Royal Hobart Hospital Foundation , an equipment grant from Philips Medical Systems and Siemens , and a project grant from GE Medical Systems . Igal A. Sebag, MD, FASE, serves on the speakers bureau for Lantheus.
PY - 2014/10/1
Y1 - 2014/10/1
KW - Biomarkers
KW - Chemotherapy
KW - Doxorubicin
KW - Early detection
KW - Left ventricular dysfunction
KW - Strain
KW - Three-dimensional echocardiography
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84921772410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921772410&partnerID=8YFLogxK
U2 - 10.1093/ehjci/jeu192
DO - 10.1093/ehjci/jeu192
M3 - Article
C2 - 25239940
AN - SCOPUS:84921772410
VL - 15
SP - 1063
EP - 1093
JO - European Heart Journal Cardiovascular Imaging
JF - European Heart Journal Cardiovascular Imaging
SN - 2047-2404
IS - 10
ER -